
    
      Following the initial approval of the GlaxoSmithKline (GSK) Biologicals' HZ/su vaccine, the
      protocol was amended to indicate that the trademark is Shingrix. In addition, the term
      "candidate" vaccine has been replaced by "study" vaccine throughout the protocol.
    
  